Wing Y K, Clifford E M, Sheehan B D, Campling G M, Hockney R A, Cowen P J
University Department of Psychiatry, Littlemore Hospital, Oxford, UK.
Psychopharmacology (Berl). 1996 Apr;124(4):377-9. doi: 10.1007/BF02247444.
We studied the effect of the selective serotonin re-uptake inhibitor (SSRI), paroxetine (20 mg daily for 16 days) on the neuroendocrine, cardiovascular, thermic and subjective responses to the 5-HT1D receptor agonist, sumatriptan (6 mg, SC). Compared to placebo injection, sumatriptan lowered plasma prolactin and oral temperature and increased diastolic blood pressure. While paroxetine increased baseline prolactin concentration, it had no effect on any of the responses to sumatriptan. In addition, paroxetine did not alter concentrations of sumatriptan in plasma. No adverse reactions resulted from the combination of sumatriptan and paroxetine. Our findings suggest that combined treatment with sumatriptan and paroxetine in the doses used in this study is not necessarily contra-indicated. In addition, short-term SSRI treatment may not desensitise 5-HT1D autoreceptors in humans.
我们研究了选择性5-羟色胺再摄取抑制剂（SSRI）帕罗西汀（每日20毫克，共16天）对5-HT1D受体激动剂舒马曲坦（6毫克，皮下注射）的神经内分泌、心血管、体温及主观反应的影响。与安慰剂注射相比，舒马曲坦降低了血浆催乳素水平和口腔温度，并升高了舒张压。虽然帕罗西汀增加了基线催乳素浓度，但对舒马曲坦的任何反应均无影响。此外，帕罗西汀并未改变血浆中舒马曲坦的浓度。舒马曲坦与帕罗西汀联合使用未产生不良反应。我们的研究结果表明，本研究中所用剂量的舒马曲坦与帕罗西汀联合治疗不一定禁忌。此外，短期SSRI治疗可能不会使人体中的5-HT1D自身受体脱敏。
